公开(公告)号：US20250154241A1

公开(公告)日：2025-05-15

申请号：US19022014

申请日：2025-01-15

Applicant: AMGEN INC.

Inventor： Michael R. Comeau ,  James F. Smothers ,  Bo-Rin P. Yoon ,  Christopher Mehlin

IPC: C07K16/24 ,  A61K39/00 ,  A61K39/395

Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.

公开(公告)号：US20160251443A1

公开(公告)日：2016-09-01

申请号：US15058738

申请日：2016-03-02

Applicant: KIRIN-AMGEN, INC.

Inventor： Joel E. Tocker ,  Jacques J. Peschon ,  David Fitzpatrick ,  James F. Smothers ,  Christopher Mehlin ,  Ai Ching Lim

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.

Abstract translation: 本发明涉及IL-17受体A（IL-17RA或IL-17R）抗原结合蛋白，例如抗体，编码所述抗原结合蛋白的多核苷酸序列，以及用于诊断和治疗IL-17受体介导的疾病的组合物和方法 一种或多种IL-17配体的活化。 本发明涉及鉴定IL-17受体A（IL-17RA或IL-17R）上的中和决定簇和与之结合的抗体。 本发明的方面还包括与本文所述的IL-17RA中和抗体竞争结合的抗体。

公开(公告)号：US20140357854A1

公开(公告)日：2014-12-04

申请号：US14459844

申请日：2014-08-14

Applicant: Amgen Inc.

Inventor： Simon Mark Jackson ,  Nigel Pelham Clinton Walker ,  Derek Evan Piper ,  Bei Shan ,  Wenyan Shen ,  Joyce Chi Yee Chan ,  Chadwick Terence King ,  Randal Robert Ketchem ,  Christopher Mehlin ,  Teresa Arazas Carabeo ,  Qiong Cao

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/44 ,  A61K31/47 ,  A61K31/505 ,  A61K31/66 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/1137 ,  A61K2300/00

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

Abstract translation: 描述了与Proprotein转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）相互作用的抗原结合蛋白。 描述了通过向PCSK9施用药学有效量的抗原结合蛋白来治疗高胆固醇血症和其它病症的方法。 描述了使用抗原结合蛋白质向PCSK9检测样品中PCSK9的量的方法。

公开(公告)号：US20140357853A1

公开(公告)日：2014-12-04

申请号：US14459768

申请日：2014-08-14

Applicant: Amgen Inc.

Inventor： Simon Mark Jackson ,  Nigel Pelham Clinton Walker ,  Derek Evan Piper ,  Bei Shan ,  Wenyan Shen ,  Joyce Chi Yee Chan ,  Chadwick Terence King ,  Randal Robert Ketchem ,  Christopher Mehlin ,  Teresa Arazas Carabeo ,  Qiong Cao

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/44 ,  A61K31/47 ,  A61K31/505 ,  A61K31/66 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/1137 ,  A61K2300/00

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

公开(公告)号：US20140357852A1

公开(公告)日：2014-12-04

申请号：US14459743

申请日：2014-08-14

Applicant: Amgen Inc.

Inventor： Simon Mark Jackson ,  Nigel Pelham Clinton Walker ,  Derek Evan Piper ,  Bei Shan ,  Wenyan Shen ,  Joyce Chi Yee Chan ,  Chadwick Terence King ,  Randal Robert Ketchem ,  Christopher Mehlin ,  Teresa Arazas Carabeo ,  Qiong Cao

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/44 ,  A61K31/47 ,  A61K31/505 ,  A61K31/66 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/1137 ,  A61K2300/00

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

公开(公告)号：US20140357850A1

公开(公告)日：2014-12-04

申请号：US14459777

申请日：2014-08-14

Applicant: Amgen Inc.

Inventor： Simon Mark Jackson ,  Nigel Pelham Clinton Walker ,  Derek Evan Piper ,  Bei Shan ,  Wenyan Shen ,  Joyce Chi Yee Chan ,  Chadwick Terence King ,  Randal Robert Ketchem ,  Christopher Mehlin ,  Teresa Arazas Carabeo ,  Qiong Cao

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/44 ,  A61K31/47 ,  A61K31/505 ,  A61K31/66 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/1137 ,  A61K2300/00

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

公开(公告)号：US20140228557A1

公开(公告)日：2014-08-14

申请号：US14261063

申请日：2014-04-24

Applicant: Amgen, Inc.

Inventor： Simon Mark Jackson ,  Nigel Pelham Clinton Walker ,  Derek Evan Piper ,  Bei Shan ,  Wenyan Shen ,  Joyce Chi Yee Chan ,  Chadwick Terence King ,  Randal Robert Ketchem ,  Christopher Mehlin ,  Teresa Arazas Carabeo ,  Qiong Cao

IPC: C12N15/113

CPC classification number: C07K16/40 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/44 ,  A61K31/47 ,  A61K31/505 ,  A61K31/66 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/1137 ,  A61K2300/00

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

公开(公告)号：US20130245235A1

公开(公告)日：2013-09-19

申请号：US13860016

申请日：2013-04-10

Applicant: AMGEN, INC.

Inventor： Simon Mark Jackson ,  Nigel Pelham Clinton Walker ,  Derek Evan Piper ,  Wenyan Shen ,  Chadwick Terence King ,  Randal Robert Ketchem ,  Christopher Mehlin ,  Teresa Arazas Carabeo

IPC: C07K16/40

CPC classification number: C07K16/40 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/44 ,  A61K31/47 ,  A61K31/505 ,  A61K31/66 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/1137 ,  A61K2300/00

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

公开(公告)号：US20130052201A1

公开(公告)日：2013-02-28

申请号：US13656392

申请日：2012-10-19

Applicant: Amgen, Inc.

Inventor： Simon Mark Jackson ,  Nigel Pelham Clinton Walker ,  Derek Evan Piper ,  Bei Shan ,  Wayne Shen ,  Joyce Chi Yee Chan ,  Chadwick Terence King ,  Randal Robert Ketchem ,  Christopher Mehlin ,  Teresa Arazas Carabeo ,  Qiong Cao

IPC: A61K39/395 ,  A61P3/06

CPC classification number: C07K16/40 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/405 ,  A61K31/44 ,  A61K31/47 ,  A61K31/505 ,  A61K31/66 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/1137 ,  A61K2300/00

Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.